Biogen

A new ALS drug, tofersen, developed by Biogen, has cleared a major hurdle in Japan. It targets ALS patients with SOD1 gene mutations, affecting about 2% of cases. This would be the first ALS drug in Japan addressing an underlying cause.

The biotechnology market, valued at USD 1.38 Trillion in 2023, is projected to reach USD 3.90 Trillion by 2031, driven by technological advancements, investment, and demand for sustainable solutions. Segments include type, product, technology, application, and region. Key trends are personalized medicine, CRISPR, sustainability, and telemedicine. Opportunities include increased funding, emerging markets, collaborations, and regulatory advancements. Major players include AstraZeneca, Gilead Sciences, Biogen, and Merck.

The global red biotechnology market was valued at USD 405.84 billion in 2024 and is projected to reach USD 649.31 billion by 2033, growing at a CAGR of 5.36%. Key drivers include advancements in gene therapy, monoclonal antibodies, and immunotherapy, as well as increased funding for R&D. Regulatory challenges and high costs remain significant constraints.

The EMA recommended lecanemab for early Alzheimer’s, focusing on patients less likely to experience ARIA side effects. If approved, it would be the first disease-modifying therapy in the EU. The drug showed modest cognitive decline slowing in early AD patients with one or no ApoE4 gene copy. Safety measures include MRI scans and a controlled access program. The UK’s NICE questioned the drug’s cost-effectiveness, while the Alzheimer Society of Ireland highlighted the need for broader support services.

The global psoriasis drug market is valued at US$ 14.08 billion in 2024, projected to grow at a CAGR of 6.9% to US$ 27.57 billion by 2034. Factors like smoking, alcohol, and cold temperatures increase psoriasis risk, driving market growth, especially in cold climates like the U.S. Key players include Amgen, Eli Lilly, and Novartis, focusing on strategic partnerships and product innovations. Corticosteroids are widely used for psoriasis treatment, prompting increased production by manufacturers.

The Red Biotechnology Market, valued at USD 492.71 billion in 2023, is projected to reach USD 997.42 billion by 2032, driven by increasing R&D spending and advancements in genomics. Key players include Merck, F. Hoffmann-La Roche AG, and Pfizer. The market focuses on medical and pharmaceutical applications, including drug discovery and genetic modification, with growth opportunities in personalized medicine and AI integration. Challenges include regulatory and ethical concerns.

Accelerated approval, despite recent controversies, has historically provided therapeutic momentum, particularly in HIV and cancer treatments. Key issues include reliance on surrogate endpoints and confirmatory trial failures, yet the pathway has led to significant drug approvals, offering hope for diseases with high unmet needs.

The article discusses the importance of enabling JavaScript for optimal app performance.

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.

The DEVOTE study's higher dose of nusinersen (50/28-mg) significantly improved motor function and slowed neurodegeneration in SMA patients, prompting Biogen to plan regulatory filings. Presented at the 2024 WMS Annual Congress, data showed faster neurofilament reduction and consistent safety profile compared to the approved 12-mg regimen.